A detailed history of Advisor Group Holdings, Inc. transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 1,015 shares of PHAT stock, worth $8,526. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,015
Previous 2,215 54.18%
Holding current value
$8,526
Previous $22,000 18.18%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$10.25 - $19.5 $12,300 - $23,400
-1,200 Reduced 54.18%
1,015 $18,000
Q2 2024

Aug 13, 2024

BUY
$8.97 - $12.05 $17,805 - $23,919
1,985 Added 863.04%
2,215 $22,000
Q1 2024

May 10, 2024

SELL
$6.21 - $11.05 $304 - $541
-49 Reduced 17.56%
230 $2,000
Q4 2023

Feb 12, 2024

SELL
$6.99 - $10.71 $17,013 - $26,068
-2,434 Reduced 89.72%
279 $2,000
Q3 2023

Nov 13, 2023

SELL
$10.26 - $15.7 $15,779 - $24,146
-1,538 Reduced 36.18%
2,713 $28,000
Q2 2023

Aug 10, 2023

BUY
$7.28 - $14.32 $29,848 - $58,712
4,100 Added 2715.23%
4,251 $60,000
Q1 2023

May 12, 2023

BUY
$6.19 - $12.36 $6 - $12
1 Added 0.67%
151 $1,000
Q4 2022

Feb 10, 2023

SELL
$9.18 - $11.53 $3,672 - $4,612
-400 Reduced 72.73%
150 $1,000
Q3 2022

Nov 14, 2022

SELL
$6.46 - $12.11 $77,591 - $145,453
-12,011 Reduced 95.62%
550 $6,000
Q2 2022

Aug 10, 2022

SELL
$6.2 - $15.5 $222,294 - $555,737
-35,854 Reduced 74.06%
12,561 $106,000
Q1 2022

May 04, 2022

BUY
$11.55 - $20.06 $535,215 - $929,560
46,339 Added 2232.13%
48,415 $659,000
Q3 2021

Nov 05, 2021

BUY
$30.69 - $36.83 $26,178 - $31,415
853 Added 69.75%
2,076 $67,000
Q3 2020

Nov 12, 2020

BUY
$29.24 - $40.19 $13,830 - $19,009
473 Added 63.07%
1,223 $45,000
Q2 2020

Aug 14, 2020

BUY
$25.06 - $54.6 $18,795 - $40,950
750 New
750 $25,000

Others Institutions Holding PHAT

About Phathom Pharmaceuticals, Inc.


  • Ticker PHAT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,175,200
  • Market Cap $329M
  • Description
  • Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...
More about PHAT
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.